[Efficacy of mequitazine (Primalan) on the relief of symptoms of allergic rhinoconjunctivitis in children. Documented clinical experience].
To assess the clinical efficacy of mequitazina in the relieve of symptoms of allergic rhinoconjunctivitis. An open, non comparative, national multicenter study (performed by pediatricians, oto-rhino-laryngologists and allergists of different states of Mexico), in order to describe the clinical experience related to treatmente efficacy with oral mequitazina in pediatric formulation about diminished characteristic symptoms of allergic rhinitis, assessed by the physician and patient. Physicians considered that efficacy was excellent in 42% of patients, very good in 38%, good in 16%, regular in 3% and bad in 0.2%. Patients assessed as: excellent in 47% of patients, very good in 35%, good in 15%, regular in 2% and bad in 1%. Only 5% of patients experienced adverse effects, which were transient and did not need treatment withdrawal. Mequitazina is an option to relieve symptoms of patients with allergic rhinoconjunctivitis.